Browse Trials
In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.
Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.
Currently viewing trials
(Last updated: October 14, 2021)
Close
Treatment
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Non-Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
Close
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
1
NEAREST SITE: 8 miles
Epic Care Partners in Cancer Care
Emeryville,CA
VISITS: 5 visits per week, for 6 weeks
PHASE: II
NCT ID: NCT03598257
Radiation Therapy With or Without Olaparib For Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer (SWOG 1706) Scientific Title
Purpose
To compare the benefits and the effects (good and bad) of using radiation therapy along with a PARP inhibitor to radiation therapy alone.
Who is this for?
People with stage III inflammatory breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily, for 6 weeks</li> <li class="seamTextUnorderedListItem">Radiation therapy, 5 days a week, for 6 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy, 5 days a week, for 6 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The PARP inhibitor being used in this study is olaparib (Lynparza®). It is approved to treat HER2-negative metastatic breast cancer in women with an inherited BRCA1/2 mutation. </li> <li class="seamTextUnorderedListItem">PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. </li> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03598257' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2018/fda-olaparib-breast-brca-mutations' target='_blank'>NCI: Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/olaparib' target='_blank'>NCI: Olaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.swog.org/clinical-trials/s1706' target='_blank'>SWOG Cancer Research Network: Trial information</a> </li></ul>
2
NEAREST SITE: 1621 miles
MD Anderson in The Woodlands
The Woodlands,TX
VISITS: Coincides with routine care
PHASE: NA
NCT ID: NCT00477100
Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer
Inflammatory Breast Cancer (IBC) Registry Scientific Title
Purpose
To collect and study blood and tissue samples and clinical data from people with newly diagnosed and untreated breast cancer, including inflammatory breast cancer.
Who is this for?
People with newly diagnosed and untreated stage I, stage II, stage III, or stage IV (metastatic) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Additional blood drawn during a routine blood draw</li> <li class="seamTextUnorderedListItem">Core, breast tissue, and skin biopsy (performed for diagnosis)</li> <li class="seamTextUnorderedListItem">Medical history interview</li> <li class="seamTextUnorderedListItem">Clinical data collected from your medical records</li> <li class="seamTextUnorderedListItem">Photographs of both breasts</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Inflammatory</span> breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen.</li> <li class="seamTextUnorderedListItem">Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for <span class="highlight">inflammatory</span> breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00477100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2006-1072.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/sites-types/ibc' target='_blank'>NCI: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li></ul>
3
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: 1 visit every 3 weeks, ongoing
PHASE: II
NCT ID: NCT02411656
Pembrolizumab for Recurrent or Metastatic HER2 Negative Breast Cancer that is also Inflammatory, Hormone Negative, or Hormone Low Expressing
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer Who Have Received Prior Chemotherapy With Clinical Response Scientific Title
Purpose
To look at the safety and effects (good and bad) of using pembrolizumab (Keytruda®).
Who is this for?
People with recurrent or metastatic (stage IV) HER2 negative breast cancer that is also inflammatory or hormone negative (ER- and PR-) or hormone low expressing (ER and/or PR 1%-10%).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">For this trial, breast cancer that tests positive for 1%-10% estrogen or progesterone receptors is called hormone low expressing. </li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as HR low expressing breast cancer. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is an immunotherapy that helps the body's immune system slow or stop cancer cell growth by blocking a protein known as programmed cell death receptor-1 (PD-1).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02411656' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAjwy7vlBRACEiwAZvdx9jIPFQgWidLA-C5wT1MzjtITa1lJzO4axMQhgd1rro0RP5g40-abvxoCQlYQA' target='_blank'>Merck Drug Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pembrolizumab' target='_blank'>NCI Drug Dictionary: Pembrolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/Inflammatory-Breast-Cancer.html' target='_blank'>Susan G. Komen: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html' target='_blank'>Susan G. Komen: Triple Negative Breast Cancer</a> </li></ul>
4
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: Visits every 1-3 weeks over 6 months
PHASE: II
NCT ID: NCT02876107
Vectibix and Chemotherapy Before Surgery for Triple Negative Inflammatory Breast Cancer
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer Scientific Title
Purpose
To see if chemotherapy combinations used to treat advanced breast cancer are more effective when given along with a targeted drug. The treatments are given before you have surgery.
Who is this for?
Women who are newly diagnosed with stage III, inflammatory triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Chemo with Vectibix for 3 months</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Panitumumab (Vectibix®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Chemo without Vectibix for 3 months</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Followed by:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AC (Adriamycin® and Cytoxan®), by IV, every 3 weeks, for 3 months</li> <li class="seamTextUnorderedListItem">followed by surgery</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The initial chemotherapy combination is carboplatin (Paraplatin®) and paclitaxel (Taxol®). </li> <li class="seamTextUnorderedListItem">It is followed by doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC. </li> <li class="seamTextUnorderedListItem">The targeted drug is panitumumab (Vectibix®).</li> <li class="seamTextUnorderedListItem">Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells only, doing less harm to normal cells. </li> <li class="seamTextUnorderedListItem">Vectibix® is currently used to treat a certain type of metastatic colorectal cancer. </li> <li class="seamTextUnorderedListItem">It is not yet known if Vectibix® will be effective as a treatment for breast cancer.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02876107' target='_blank'>ClinicalTrials.gov</a> </li></ul>
5
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: 1 visit every 3 weeks, ongoing
PHASE: II
NCT ID: NCT02971748
Adding Immunotherapy to Anti-Estrogen Therapy for Stage III Hormone Positive, HER2 Negative Inflammatory Breast Cancer
A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy Scientific Title
Purpose
To study the effects (good and bad) of treating inflammatory breast cancer with an immunotherapy in addition to anti-estrogen therapy.
Who is this for?
People with hormone receptor-positive (ER+ and/or PR+), HER2 negative (HER2-) inflammatory breast cancer. You must have received chemotherapy before breast surgery, and tumor cells must have been still present after you finished chemotherapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Doctor's choice of hormone therapy, by mouth, daily, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy used in this study is pembrolizumab (Keytruda®).</li> <li class="seamTextUnorderedListItem">Your doctor will choose which anti-estrogen drug you will receive: tamoxifen (Nolvadex®), exemestane (Aromasin®), anastrozole (Arimidex®), or letrozole (Femara®.</li> <li class="seamTextUnorderedListItem">If you are premenopausal, you may also receive a therapy that will stop your ovaries from producing estrogen and put you into menopause.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02971748' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancer-types/inflammatory-breast-cancer.html' target='_blank'>MD Anderson Inflammatory Breast Cancer Clinic</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Inflammatory Breast Cancer</a> </li></ul>
6
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: Weekly visits
PHASE: I-II
NCT ID: NCT03101748
Adding Neratinib for Advanced or Inflammatory Breast Cancer
A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC Scientific Title
Purpose
To investigate the safety and best dose of neratinib (Nerlynx®) to add to drug regimens used to treat advanced breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that is HER2-positive. If you have inflammatory breast cancer, your tumor can be either HER2 positive (HER2+) or HER2 negative (HER2-) so long as its also hormone receptor positive (ER+ and/or PR+).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: HER2 Positive</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Keep a medication diary about neratinib</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: HER2 Positive <span class="highlight">Inflammatory</i></span> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Doxorubicin and cyclophosphamide, by IV, monthly</li> <li class="seamTextUnorderedListItem">followed by surgery</li> <li class="seamTextUnorderedListItem">Keep a medication diary about neratinib</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: HER2 Negative/ER Positive <span class="highlight">Inflammatory</i></span> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly</li> <li class="seamTextUnorderedListItem">Doxorubicin and cyclophosphamide, by IV, monthly</li> <li class="seamTextUnorderedListItem">followed by surgery</li> <li class="seamTextUnorderedListItem">Keep a medication diary about neratinib</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is a tyrosine kinase inhibitor approved for use in patients with HER2 positive (HER2+) breast cancer</li> <li class="seamTextUnorderedListItem">The HER2-targeted drugs used in this study are pertuzumab (Perjeta®) and Herceptin. </li> <li class="seamTextUnorderedListItem">The chemotherapies used in this study are doxorubicin/Adriamicin® and cyclophosphamide/Cytoxan®. </li> <li class="seamTextUnorderedListItem">Your treatment regimen will be determined by whether your tumor is HER2+ or HER2- and if you have <span class="highlight">inflammatory</span> breast cancer. </li> <li class="seamTextUnorderedListItem">Women with <span class="highlight">inflammatory</span> breast cancer will also have surgery.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03101748' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/inside-oncology/adam-brufsky-md/neratinib-for-metastatic-breast-cancer' target='_blank'>OncLive: Neratinib for Metastatic Breast Cancer (Video)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/neratinib-improves-pfs-in-her2-metastatic-breast-cancer' target='_blank'>OncLive: Neratinib Improves PFS in HER2+ MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancer-news.com/pb272-neratinib/' target='_blank'>Breast Cancer News: Neratinib</a> </li></ul>
7
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: 1 visit every week to 2 weeks, ongoing
PHASE: II
NCT ID: NCT03202316
Atezolizumab, Cobimetinib & Eribulin for Metastatic Inflammatory Breast Cancer
A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer Scientific Title
Purpose
To determine the safety and effects (good and bad) of a combination therapy including chemotherapy, immunotherapy, and targeted therapies.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) inflammatory breast cancer. If your cancer is HER2 positive (HER2+), you must have received at least two anti-HER2 therapies, including pertuzumab (Perjeta®) and trastuzumab emtansine/T-DM1 (Kadcyla®).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">First 2 weeks</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once</li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), by IV, 8 times over 3.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Followed by</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®), mouth, weekly (3 weeks on, 1 week off), ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. </li> <li class="seamTextUnorderedListItem">FDA has approved Tecentriq® to treat certain types of bladder and lung cancer. </li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®) is a new targeted therapy called an MEK inhibitor. It is approved to treat certain types of melanoma. </li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) is a chemotherapy approved for treating metastatic breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03202316' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tecentriq.com' target='_blank'>Genentech Information Page: Tecentriq</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Cobimetinib' target='_blank'>Wikipedia: Cobimetinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cotellic.com' target='_blank'>Genentech Information Page: Cotellic</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.halaven.com/metastatic-breast-cancer' target='_blank'>Drug Company Information Page: Halaven</a> </li></ul>
8
NEAREST SITE: 1739 miles
Washington University School of Medicine
Saint Louis,MO
VISITS: 3 to 8 visits a month, ongoing
PHASE: II
NCT ID: NCT04215146
Pelareorep with Taxol or with Taxol & Avelumab for Advanced HR+, HER2- Breast Cancer
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study (PrE0113) Scientific Title
Purpose
To study the safety and anti-cancer activity of the experimental immunotherapy pelareorep when it is given in combination with paclitaxel (Taxol®) or paclitaxel (Taxol®) and the PD-L1 inhibitor avelumab (Bavencio®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose disease progressed after they received a CDK 4/6 inhibitor in combination with hormone therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pelareorep, by IV, 2 days a week (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pelareorep, by IV, 2 days a week (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®), by IV, every 2 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy used for advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Avelumab (Bevancio®) is an immunotherapy that works by stimulating the body's immune system to go after cancer cells by blocking a protein called PD-L1.</li> <li class="seamTextUnorderedListItem">Pelareorep is an oncolytic virus--this means it targets and kills cancer cells. It may directly kill cancer cells and stimulate your immune system to go after and kill cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04215146' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Pelareorep' target='_blank'>Wikipedia: Pelareorep</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Avelumab' target='_blank'>Wikipedia: Avelumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/paclitaxel-taxol' target='_blank'>Breast Cancer Now: Paclitaxel</a> </li></ul>
9
NEAREST SITE: 2108 miles
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Wexner Medical Center
Columbus,OH
VISITS: At least 2 visits
PHASE: NA
NCT ID: NCT02415387
Typhoid Vaccine to Study Immune Response in Patients Who Received Chemotherapy
The IMPACT Study: Inflammatory Responses, Mood and Physical Fitness After Cancer Treatment Scientific Title
Purpose
To investigate how women who have completed treatment for early-stage breast cancer respond to a typhoid vaccine by measuring their cardiorespiratory fitness, natural inflammatory reaction, and behavioral responses such as depression, fatigue, pain, and problems with thinking and reasoning.
Who is this for?
Women who are postmenopausal and have received chemotherapy as part of breast cancer treatment.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> Participants will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typhoid vaccine, by injection, on first visit</li> <li class="seamTextUnorderedListItem">followed by placebo, by injection, on second visit (2 weeks to 1 month later)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by injection, on first visit</li> <li class="seamTextUnorderedListItem">followed by typhoid vaccine, by injection, on second visit (2 weeks to 1 month later)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy can weaken the body's immune system. </li> <li class="seamTextUnorderedListItem">Physical fitness may protect the body from the effects that chemotherapy has on the immune system as well as reduce other health problems. </li> <li class="seamTextUnorderedListItem">Giving patients a typhoid vaccine allows researchers to study their immune response.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02415387' target='_blank'>ClinicalTrials.gov</a> </li></ul>
10
NEAREST SITE: 2693 miles
Brigham and Women's Hospital
Boston,MA
VISITS: 1 visit every 6 months, for 2 years
PHASE: NA
NCT ID: NCT04030507
Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer
Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study Scientific Title
Purpose
To study if using MRIs to screen for brain metastases (breast cancer that has spread to the brain) is safe and finds brain metastases earlier than the standard of care (no screening).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who will be starting their first or second chemotherapy for advanced disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups depending upon your cancer subtype: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Triple negative</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: <span class="highlight">Inflammatory</i></span> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Hormone positive or HER2 positive</i> </p> <p class="seamTextPara"> People in Group 3 will be randomly assigned to receiving screening or no screening </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Screening group</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">No screening group</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No brain MRIs</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic breast cancer does not include ongoing screening for brain metastases.</li> <li class="seamTextUnorderedListItem">This imaging trial will use regularly scheduled MRIs (magnetic resonance imaging) to look for brain mets.</li> <li class="seamTextUnorderedListItem">Researchers believe adding brain metastases screening to the standard of care will help doctors find brain mets earlier--when they are smaller and potentially easier to manage.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04030507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mri/about/pac-20384768' target='_blank'>Mayo Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologybusiness.com/topics/policy/brain-mri-could-id-metastases-breast-cancer-patients-guidelines-dont-recommend-it' target='_blank'>Radiology Business: Brain MRI Could ID Metastases in Breast Cancer Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/Pages/Spring2019/Looking-for-Brain-Metastases.aspx' target='_blank'>Cancer Today: Looking for Brain Metastases</a> </li></ul>
